+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Multidrug-resistant Tuberculosis Therapeutics Market by Offering (Medication, Therapies), Mode of Administration (Injectable Medications, Oral Medications), Distribution Channel - Forecast 2024-2030- Product Image
Global Multidrug-resistant Tuberculosis Therapeutics Market by Offering (Medication, Therapies), Mode of Administration (Injectable Medications, Oral Medications), Distribution Channel - Forecast 2024-2030- Product Image
Sale

Global Multidrug-resistant Tuberculosis Therapeutics Market by Offering (Medication, Therapies), Mode of Administration (Injectable Medications, Oral Medications), Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5968090
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multidrug-resistant Tuberculosis Therapeutics Market size was estimated at USD 281.00 million in 2023, USD 311.32 million in 2024, and is expected to grow at a CAGR of 11.14% to reach USD 588.62 million by 2030.

Multidrug-resistant tuberculosis (MDR-TB) therapeutics refers to the treatment strategies and medications employed to combat tuberculosis (TB) strains that have developed resistance to at least the two most potent anti-tuberculosis drugs, isoniazid and rifampicin. These drugs are the cornerstone of standard tuberculosis treatment, and resistance to them complicates the treatment process significantly, necessitating the use of alternative medications. MDR-TB therapeutics typically involve a longer treatment duration, often lasting up to 24 months, and the use of second-line drugs, which can be more expensive, less effective, and carry a higher risk of side effects compared to the first-line drugs used for drug-sensitive TB.

The rising incidences of tuberculosis, particularly in developing countries, directly correlate with heightened demand for effective MDR-TB treatments. Moreover, increased funding, awareness campaigns, and supportive policies from governments and non-government organizations worldwide have significantly contributed to market growth. However, the elevated cost of newer, more effective drugs limits access in low-income countries, directly impacting market growth. The evolution of extensively drug-resistant TB strains poses a substantial hurdle, necessitating continuous research and development efforts. Furthermore, innovations in drug development and diagnostic technologies have enhanced the efficacy and accessibility of MDR-TB treatments.

Regional Insights

The United States and Canada represent the Americas in the battle against MDR-TB. Though the incidence rates in these countries are relatively lower compared to the Asia Pacific and EMEA regions, they highlight a different set of challenges and consumer needs. In the United States, the focus is on the integration of advanced diagnostic techniques and the development of novel therapeutics backed by significant research funding and patent filings that aim to bring innovative treatments to the market. In the EU countries, the approach towards MDR-TB involves a combination of advanced healthcare infrastructure, robust public health policies, and research initiatives.

The emphasis is on early detection, personalized medicine, and the integration of new drugs and regimens into treatment protocols. Consumer behavior is characterized by a high level of trust in the healthcare system and a willingness to participate in vaccination and preventive measures. The Middle East faces unique challenges, including variable reporting quality and access to healthcare services. Efforts are concentrated on strengthening healthcare systems, improving diagnostic accuracy, and increasing public awareness. China, Japan, and India are key countries in the Asia Pacific region significantly impacted by multidrug-resistant tuberculosis (MDR-TB). This region witnesses a high incidence rate, contributing to a considerable demand for effective therapeutics. Consumer needs in these countries are driven by the urgent necessity for accessible, affordable, and efficient treatment options.

Market Trends by Segment

  • Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis
  • Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Expanding Global Access to Groundbreaking DR-TB Treatment Through Strategic Partnerships

Macleods Pharmaceuticals has emerged as a pivotal figure in the fight against drug-resistant tuberculosis (DR-TB), marking a significant milestone as the second manufacturer globally to launch pretomanid. Securing a licensing agreement with TB Alliance, Macleods is positioned to supply pretomanid to 135 low- and middle-income nations, bolstering efforts to combat one of the world's most challenging infectious diseases. The advent of Macleods' pretomanid production amplifies the availability of this vital drug, facilitating the broader adoption and implementation of the BPaL regimen across over 70 countries currently engaging in procurement processes.

Breakthrough in Global Fight Against MDR TB: Bedaquiline Patents Waived to Enhance Access in Low- and Middle-Income Countries

Johnson & Johnson (J&J) has agreed to relax enforcement of its patents on bedaquiline, a key drug in treating multidrug-resistant tuberculosis (MDR TB), thereby facilitating the production of generic versions in numerous low- and middle-income countries (LMICs). This announcement, made by the Stop TB Partnership's Global Drug Facility (GDF), marks a significant step towards making this essential treatment more accessible and affordable.

Breakthrough in Combating Gram-Negative Bacterial Infections with Aztreonam-Avibactam’s Clinical Triumphs

Pfizer Inc. has unveiled promising outcomes from its robust Phase 3 clinical trials, specifically the REVISIT and ASSEMBLE studies, involving the novel antibiotic combination aztreonam-avibactam (ATM-AVI). This drug duo showcased efficacy, safety, and tolerability in addressing severe bacterial infections precipitated by Gram-negative bacteria, particularly those strains equipped with Metallo-β-lactamase (MBL), notorious for their multidrug-resistant nature. The studies revealed that ATM-AVI holds a comparable safety profile to aztreonam alone and bears no new safety concerns, marking a significant stride in the fight against antimicrobial resistance (AMR) - a looming global health menace.

Key Company Profiles

The report delves into recent significant developments in the Multidrug-resistant Tuberculosis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, Daiichi Sankyo Co., Ltd., Endo International Plc, Johnson & Johnson Services Inc., Lupin Limited, Macleods Pharmaceuticals Ltd., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi SA, and Santen Pharmaceutical Co., Ltd.

This research report offers invaluable insights into various crucial aspects of the Multidrug-resistant Tuberculosis Therapeutics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of tuberculosis across the globe
5.1.1.2. Growing emphasis is on early detection and personalized medicine
5.1.1.3. Increasing research & development activities for new drug development
5.1.2. Restraints
5.1.2.1. High cost of MDR drugs coupled with the limited reimbursement options
5.1.3. Opportunities
5.1.3.1. Increasing initiative from government organization for tuberculosis awareness
5.1.3.2. Technological advancement in the diagnostics procedures
5.1.4. Challenges
5.1.4.1. Complexities associated with the treatment of multidrug-resistant tuberculosis
5.2. Market Segmentation Analysis
5.2.1. Offering: Ongoing research activities boosting the development of innovative therapies to treat multidrug-resistant tuberculosis
5.2.2. Distribution Channel: Growing significance of offline distribution channel as it provide close medical supervision
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Multidrug-resistant Tuberculosis Therapeutics Market, by Offering
6.1. Introduction
6.2. Medication
6.3. Therapies
7. Multidrug-resistant Tuberculosis Therapeutics Market, by Mode of Administration
7.1. Introduction
7.2. Injectable Medications
7.3. Oral Medications
8. Multidrug-resistant Tuberculosis Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Offline
8.3. Online
9. Americas Multidrug-resistant Tuberculosis Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Multidrug-resistant Tuberculosis Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Multidrug-resistant Tuberculosis Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Expanding Global Access to Groundbreaking DR-TB Treatment Through Strategic Partnerships
12.3.2. Breakthrough in Global Fight Against MDR TB: Bedaquiline Patents Waived to Enhance Access in Low- and Middle-Income Countries
12.3.3. Breakthrough in Combating Gram-Negative Bacterial Infections with Aztreonam-Avibactam’s Clinical Triumphs
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET DYNAMICS
FIGURE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
FIGURE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DELAMANID, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PRETOMANID, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY THERAPIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 55. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 56. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 57. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 58. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 59. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 60. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 65. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 66. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 67. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 68. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 69. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 70. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 75. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 76. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 77. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 78. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 79. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 80. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 81. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 82. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 83. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 84. CANADA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 85. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 86. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 87. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 88. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 89. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 90. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 91. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 92. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 93. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 94. MEXICO MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 95. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 96. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 97. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 98. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 99. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 100. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 101. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 102. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 108. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 110. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 112. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 114. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 119. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 120. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 121. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 122. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 123. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 124. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 125. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 126. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 129. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 130. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 131. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 132. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 133. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 134. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 135. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 136. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 137. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 138. CHINA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 139. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 140. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 141. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 142. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 143. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 144. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 145. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 146. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 147. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 148. INDIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 149. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 150. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 151. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 152. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 153. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 154. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 155. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 156. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 159. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 160. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 161. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 162. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 163. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 164. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 165. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 166. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 167. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 168. JAPAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 169. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 170. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 171. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 172. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 173. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 174. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 175. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 176. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 179. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 180. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 181. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 182. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 183. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 184. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 185. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 186. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 189. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 190. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 191. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 192. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 193. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 194. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 195. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 196. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 199. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 200. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 201. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 202. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 203. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 204. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 205. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 206. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 209. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 210. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 211. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 212. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 213. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 214. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 215. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 216. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 219. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 220. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 221. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 222. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 223. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 224. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 225. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 226. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 227. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 228. THAILAND MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 229. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 230. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 231. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 232. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 233. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 234. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 235. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 236. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 251. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 252. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 253. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 254. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 255. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 256. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 257. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 258. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 259. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 260. DENMARK MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 261. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 262. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 263. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
TABLE 264. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
TABLE 265. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 266. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 267. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 268. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 269. EGYPT MULTIDRUG-RESISTANT TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABL

Companies Mentioned

  • Abcam Limited
  • Daiichi Sankyo Co., Ltd.
  • Endo International Plc
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 311.32 Million
Forecasted Market Value ( USD ) by 2030 $ 588.62 Million
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032 - Product Image

Anti Tuberculosis Therapeutics Market Report and Forecast 2024-2032

  • Report
  • 180 Pages
  • Global
From
Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 190 Pages
  • Global
From
Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region and Competition - Product Image

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region and Competition

  • Report
  • 113 Pages
  • Global
From
Anti-Tuberculosis Therapeutics Market by Disease Type, Diagnosis and Treatment, End User, and Region 2023-2028 - Product Image

Anti-Tuberculosis Therapeutics Market by Disease Type, Diagnosis and Treatment, End User, and Region 2023-2028

  • Report
  • 139 Pages
  • Global
From
Tuberculosis Therapeutics - Global Strategic Business Report - Product Image

Tuberculosis Therapeutics - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.